First 90 Days
-
Permission granted by Verastem
Q&A // First 90 DaysWith an ovarian KRAS combo ready for review, Verastem’s CEO is poised for the transition
As its FDA filing approaches, Verastem Oncology CEO Daniel Paterson wants to go from “The Little Engine That Could” to a major oncology player.
By Michael Gibney • April 4, 2024 -
Permission granted by Organon
Q&A // First 90 DaysOrganon’s chief medical officer wants to change how the world sees women’s health
Dr. Juan Camilo Arjona Ferreira joined Organon in September and says the company is “like a lighthouse in women’s health” in its visibility and focus.
By Michael Gibney • Nov. 22, 2023 -
Stock via Getty Images
Q&A // First 90 DaysWhy Senda’s new chief medical officer says targeted delivery tech is like ‘science fiction’
The Flagship-backed biotech believes the secret to more precise drug delivery lies in the nanoparticles of plants and fungi.
By Alexandra Pecci • Sept. 26, 2023 -
Stock via Getty Images
Q&A // First 90 DaysA rare disease veteran, Inozyme’s new CEO sharpens the company’s focus
After taking the reins from the company’s founding CEO, Douglas Treco is guiding Inozyme through the clinic.
By Alexandra Pecci • July 11, 2023 -
Stock via Getty Images
Q&A // First 90 DaysA BMS exec’s journey around the world in 90 days
As BMS grapples with upcoming patent cliffs, Emma Charles, the new SVP of intercontinental markets, is focused on expanding its footprint.
By Karissa Waddick • July 5, 2023 -
Permission granted by Genmab
Q&A // First 90 DaysFrom science to strategy, this exec is painting Genmab’s bigger picture into the next decade
Martine van Vugt, recently named Genmab’s chief strategy officer and executive vice president, aims to usher in the company’s next wave of "knock your socks off" antibodies.
By Michael Gibney • May 2, 2023 -
iStock via Getty Images
Q&A // First 90 DaysThe ‘recovering academic’ leading Allogene to the next stage of cell therapy
Zachary Roberts joined Allogene at the beginning of this year to lead the company's R&D and bring allogeneic cell therapy to the forefront.
By Michael Gibney • March 2, 2023 -
Permission granted by Klick Group
Q&A // First 90 DaysBrian Fox is bringing ‘fresh eyes’ to ad agency Klick
Why the recently appointed president of commercial solutions sees near limitless potential to expand Klick’s footprint across the life sciences — and how generative AI is playing a role.
By Karissa Waddick • Feb. 13, 2023 -
Permission granted by Entact Bio
Q&A // First 90 DaysEntact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement
Victoria Richon’s latest venture is in the burgeoning field of protein-enhancing drugs that could target a range of diseases.
By Kelly Bilodeau • Feb. 6, 2023 -
Stock via Getty Images
Q&A // First 90 DaysDr. Sy Pretorius, Eversana’s new COO, is flipping the script on his career
With a long history in the clinical space, Pretorius is now applying those deep insights to the commercial side of the business.
By Taren Grom • Dec. 9, 2022 -
iStock via Getty Images
Q&A // First 90 DaysComing out of stealth, RIGImmune aims to catch up with ever-mutating viruses
President Susan Sobolov discusses how the startup is building on the work of two powerhouse Yale scientists to advance candidates for viruses — and beyond.
By Kelly Bilodeau • Oct. 13, 2022 -
joel-t via Getty Images
First 90 DaysFirst 90 Days: Adaptive Biotech’s Tycho Peterson
A long-time analyst, Tycho Peterson brings his business savvy to the C-suite at Adaptive, where he began as CFO in June with a knowledge of what works and what doesn't in the diagnostics space.
By Michael Gibney • Sept. 1, 2022 -
Permission granted by Brian Goff.
Q&A // First 90 DaysFirst 90 Days: Agios Pharmaceuticals’ Brian Goff
The rare disease veteran and first-time CEO is bringing his expertise to the company as it launches the first FDA-approved treatment for pyruvate kinase (PK) deficiency.
By Alexandra Pecci • Aug. 22, 2022 -
Stock via Getty Images
Q&A // First 90 DaysAnjarium Biosciences’ CEO on its next-gen gene therapies
Stephen Yoo aims to build on the buzz around the company’s leading-edge gene therapy tech.
By Kim Ribbink • July 15, 2022 -
Permission granted by Editas/Gilmore O'Neill
Q&A // First 90 DaysFirst 90 Days: Editas Medicine’s Gilmore O’Neill
The first-time CEO is flexing new muscles as he steers the gene editing company through clinical trials and beyond.
By Michael Gibney • June 13, 2022 -
Permission granted by David Jimenez.
Q&A // First 90 DaysFirst 90 Days: Janssen Immunology’s David Jimenez
The long-time company man discusses the mega-drugmaker’s plans for growth and why, if you meet with him, you should plan on sipping coffee.
By Taren Grom • June 6, 2022 -
Permission granted by Sosei Heptares/Chris Cargill
Q&A // First 90 DaysFirst 90 Days: Sosei Heptares’ Chris Cargill
The company’s new CEO is looking to drive growth through collaboration and transparency.
By Kim Ribbink • May 31, 2022 -
Permission granted by Michelle Keefe.
Q&A // First 90 DaysFirst 90 Days: Syneos Health’s Michelle Keefe
The newly minted CEO is leaning on her 30 years of experience leading high-performance teams to make her mark at Syneos.
By Taren Grom • May 23, 2022 -
Real Chemistry/PharmaVoice
Q&ALessons from improv: Shankar Narayanan’s ‘yes, and’ approach to healthcare leadership
Real Chemistry's CEO is bringing a unique set of skills to the role as he sets off on a company-wide listening tour.
By Taren Grom • April 4, 2022 -
Retrieved from PharmaVOICE on March 21, 2022
Q&ABioMarin’s new global head of advocacy is tackling the holy grail of patient engagement
In her new role, Dr. Roz is keeping her patient-first approach.
By Taren Grom • March 21, 2022 -
Permission granted by Peter Anastasiou
Q&A // First 90 DaysNew Capsida Biotherapeutics CEO Peter Anastasiou aims to bring AAV therapy to reality
Read what Capsida CEO Peter Anastasiou has planned for his new role.
By Taren Grom • Feb. 3, 2022
